Navigation

Breast cancer (HER2 negative, metastatic) - bevacizumab (2nd line) [ID488]

Bevacizumab for the second line treatment of HER2 negative metastatic breast cancer

Status: Suspended
Expected date of issue: TBC
Referral date: November 2011
Process: STA
Notes:

Scoped within Batch 19

Topic area:
  • Cancer
 

NICE project team

Executive Lead: TBC
Technical Lead: TBC
Communications manager: TBC
Project manager: TBC
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC
Top


 

Consultees and commentators

To be confirmed

Top


 

Project history

Date Update
7 November 2011

As you will be aware, the Department of Health has asked the Institute to conduct an appraisal of bevacizumab in combination with chemotherapy for the second line treatment of human epidermal growth factor 2 (HER2) negative metastatic breast cancer as part of our 27th work programme. 

The Institute has now been informed by the manufacturer that it has decided not to apply for a centralised marketing authorisation for this indication. NICE has therefore decided to suspend this appraisal on its current work programme for the time being.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.

Top


 

Key documents

This page was last updated: 28 February 2012

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.